- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
UHRF1 is a mediator of KRAS driven oncogenesis in lung adenocarcinoma ; volume:14 ; number:1 ; day:5 ; month:7 ; year:2023 ; pages:1-18 ; date:12.2023
Nature Communications ; 14, Heft 1 (5.7.2023), 1-18, 12.2023
- Creator
-
Kostyrko, Kaja
Román, Marta
Lee, Alex G.
Simpson, David R.
Dinh, Phuong T.
Leung, Stanley G.
Marini, Kieren D.
Kelly, Marcus R.
Broyde, Joshua
Califano, Andrea
Jackson, Peter K.
Sweet-Cordero, E. Alejandro
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41467-023-39591-2
- URN
-
urn:nbn:de:101:1-2024020210515957964607
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
2025-08-15T07:37:16+0200
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kostyrko, Kaja
- Román, Marta
- Lee, Alex G.
- Simpson, David R.
- Dinh, Phuong T.
- Leung, Stanley G.
- Marini, Kieren D.
- Kelly, Marcus R.
- Broyde, Joshua
- Califano, Andrea
- Jackson, Peter K.
- Sweet-Cordero, E. Alejandro
- SpringerLink (Online service)
Other Objects (12)
RIPK3 suppresses Kras-driven pulmonary adenoma and adenocarcinoma formation
Oncogenesis
Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis
Identification of effectors of the serine/threonine kinase STK33 involved in KRAS-mediated oncogenesis
Inhibition of MCL-1 blocks the development of KRAS-driven adenocarcinoma of the lung
Nf1 loss promotes Kras ‐driven lung adenocarcinoma and results in Psat1‐mediated glutamate dependence
Unraveling (K)RAS in pancreatic ductal adenocarcinoma
Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis
Phosphorylated SHMT2 Regulates Oncogenesis Through m 6 A Modification in Lung Adenocarcinoma
A comprehensive enhancer screen identifies TRAM2 as a key and novel mediator of YAP oncogenesis
Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma
STK11 loss leads to YAP1-mediated transcriptional activation in human KRAS-driven lung adenocarcinoma cell lines
RIPK3 suppresses Kras-driven pulmonary adenoma and adenocarcinoma formation
Oncogenesis
Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis
Identification of effectors of the serine/threonine kinase STK33 involved in KRAS-mediated oncogenesis
Inhibition of MCL-1 blocks the development of KRAS-driven adenocarcinoma of the lung
Nf1 loss promotes Kras ‐driven lung adenocarcinoma and results in Psat1‐mediated glutamate dependence
Unraveling (K)RAS in pancreatic ductal adenocarcinoma
Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis
Phosphorylated SHMT2 Regulates Oncogenesis Through m 6 A Modification in Lung Adenocarcinoma
A comprehensive enhancer screen identifies TRAM2 as a key and novel mediator of YAP oncogenesis
Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma
STK11 loss leads to YAP1-mediated transcriptional activation in human KRAS-driven lung adenocarcinoma cell lines
RIPK3 suppresses Kras-driven pulmonary adenoma and adenocarcinoma formation
Oncogenesis
Significance of KRAS/PAK1/Crk pathway in non-small cell lung cancer oncogenesis
Identification of effectors of the serine/threonine kinase STK33 involved in KRAS-mediated oncogenesis
Inhibition of MCL-1 blocks the development of KRAS-driven adenocarcinoma of the lung
Nf1 loss promotes Kras ‐driven lung adenocarcinoma and results in Psat1‐mediated glutamate dependence
Unraveling (K)RAS in pancreatic ductal adenocarcinoma
Molecular mechanisms of EBV-driven cell cycle progression and oncogenesis
Phosphorylated SHMT2 Regulates Oncogenesis Through m 6 A Modification in Lung Adenocarcinoma
A comprehensive enhancer screen identifies TRAM2 as a key and novel mediator of YAP oncogenesis
Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma